NeuBase Therapeutics, Inc. - FORM 10-K - EX-23 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - January 3, 2019

Attached files

file filename
10-K - ANNUAL REPORT - NeuBase Therapeutics, Inc.ohr-10k_093018.htm
EX-32.2 - SECTION 906 CERTIFICATION OF CHIEF FINANCIAL OFFICER - NeuBase Therapeutics, Inc.ex32-2.htm
EX-32.1 - SECTION 906 CERTIFICATION OF CHIEF EXECUTIVE OFFICER - NeuBase Therapeutics, Inc.ex32-1.htm
EX-31.2 - SECTION 302 CERTIFICATION OF CHIEF FINANCIAL OFFICER - NeuBase Therapeutics, Inc.ex31-2.htm
EX-31.1 - SECTION 302 CERTIFICATION OF CHIEF EXECUTIVE OFFICER - NeuBase Therapeutics, Inc.ex31-1.htm
EX-21 - SUBSIDIARIES OF THE REGISTRANT - NeuBase Therapeutics, Inc.ex-21.htm

 

Ohr Pharmaceutical, Inc. 10-K

 

Exhibit 23

Consent of Independent Registered Public Accounting Firm

 

We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333- 220487) and Form S-8 (No. 333-215382) of Ohr Pharmaceutical, Inc. of our report dated January 3, 2019, relating to the consolidated financial statements for the year ended September 30, 2018, which report appears in this Annual Report on Form 10-K for the fiscal year ended September 30, 2018. 

 
/s/ MaloneBailey, LLP
www.malonebailey.com
Houston, Texas
January 3, 2019

 

 

 

 

NeuBase Therapeutics, Inc. Reports